Petar Đurić, Verica Jovanović, Mitra B Drakulović, Dragana Plavša, Jovan Malinić, Aleksandar Medarević, Jelena Protić, Nana Mebonia
{"title":"塞尔维亚的麻疹病例，2022年。","authors":"Petar Đurić, Verica Jovanović, Mitra B Drakulović, Dragana Plavša, Jovan Malinić, Aleksandar Medarević, Jelena Protić, Nana Mebonia","doi":"10.3390/idr17010009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>On 23 July 2022, the World Health Organization (WHO) declared the mpox multi-country outbreak as a Public Health Emergency of International Concern. This study aimed to identify the epidemiological and clinical characteristics of confirmed mpox cases reported in Serbia in 2022.</p><p><strong>Methods: </strong>The mpox WHO case definition was used. Incidence rates (IRs) and incidence rate ratios (IRRs) by age groups and nomenclature of territorial units for statistics level 3 (NUTS-3) with 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Between June and October 2022, 43 laboratory-confirmed cases were reported. All were unvaccinated males, with the mean age of 34 (±7.4) years. Out of the total, 72.1% cases were men who have sex with men (MSM), who reported sexual intercourse either with multiple or unknown partners (<i>p</i> < 0.01). Fifteen cases (34.9%) lived with HIV, mostly in the 30-39 age group (<i>p</i> = 0.023). People living in Belgrade City NUTS-3 were six times more likely to become infected compared to South Backa citizens (IRR: 6.03, 95% CI: 1.47-25.53).</p><p><strong>Conclusions: </strong>In Serbia, mpox mainly affected MSM aged 30-39 and living in urban areas. Health promotion and vaccine implementation should be prioritized in populations with a higher risk.</p>","PeriodicalId":13579,"journal":{"name":"Infectious Disease Reports","volume":"17 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11855485/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mpox Cases in Serbia, 2022.\",\"authors\":\"Petar Đurić, Verica Jovanović, Mitra B Drakulović, Dragana Plavša, Jovan Malinić, Aleksandar Medarević, Jelena Protić, Nana Mebonia\",\"doi\":\"10.3390/idr17010009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>On 23 July 2022, the World Health Organization (WHO) declared the mpox multi-country outbreak as a Public Health Emergency of International Concern. This study aimed to identify the epidemiological and clinical characteristics of confirmed mpox cases reported in Serbia in 2022.</p><p><strong>Methods: </strong>The mpox WHO case definition was used. Incidence rates (IRs) and incidence rate ratios (IRRs) by age groups and nomenclature of territorial units for statistics level 3 (NUTS-3) with 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Between June and October 2022, 43 laboratory-confirmed cases were reported. All were unvaccinated males, with the mean age of 34 (±7.4) years. Out of the total, 72.1% cases were men who have sex with men (MSM), who reported sexual intercourse either with multiple or unknown partners (<i>p</i> < 0.01). Fifteen cases (34.9%) lived with HIV, mostly in the 30-39 age group (<i>p</i> = 0.023). People living in Belgrade City NUTS-3 were six times more likely to become infected compared to South Backa citizens (IRR: 6.03, 95% CI: 1.47-25.53).</p><p><strong>Conclusions: </strong>In Serbia, mpox mainly affected MSM aged 30-39 and living in urban areas. Health promotion and vaccine implementation should be prioritized in populations with a higher risk.</p>\",\"PeriodicalId\":13579,\"journal\":{\"name\":\"Infectious Disease Reports\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-01-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11855485/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Disease Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/idr17010009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Disease Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/idr17010009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Background: On 23 July 2022, the World Health Organization (WHO) declared the mpox multi-country outbreak as a Public Health Emergency of International Concern. This study aimed to identify the epidemiological and clinical characteristics of confirmed mpox cases reported in Serbia in 2022.
Methods: The mpox WHO case definition was used. Incidence rates (IRs) and incidence rate ratios (IRRs) by age groups and nomenclature of territorial units for statistics level 3 (NUTS-3) with 95% confidence intervals (CIs) were calculated.
Results: Between June and October 2022, 43 laboratory-confirmed cases were reported. All were unvaccinated males, with the mean age of 34 (±7.4) years. Out of the total, 72.1% cases were men who have sex with men (MSM), who reported sexual intercourse either with multiple or unknown partners (p < 0.01). Fifteen cases (34.9%) lived with HIV, mostly in the 30-39 age group (p = 0.023). People living in Belgrade City NUTS-3 were six times more likely to become infected compared to South Backa citizens (IRR: 6.03, 95% CI: 1.47-25.53).
Conclusions: In Serbia, mpox mainly affected MSM aged 30-39 and living in urban areas. Health promotion and vaccine implementation should be prioritized in populations with a higher risk.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
